Sotyktu PsA Data Reinforces Incremental Growth, Not a Thesis Changer

What happened

Bristol Myers Squibb presented two-year data for Sotyktu (deucravacitinib) at a medical conference, showing durable efficacy and consistent safety in adults with psoriatic arthritis. The news is a positive but incremental clinical update for a product already in the Growth Portfolio, where Sotyktu has shown only modest growth (+4% in Q4 2025). While longer-term data may support commercial positioning, it does not address the company's central challenges: Eliquis pricing pressure from the Inflation Reduction Act, Revlimid generic erosion accelerating after January 31, 2026, and the need to defend gross margin near 69–70% in 2026. Investor focus remains on quarterly financial execution and policy risk, not isolated efficacy data. This presentation is unlikely to materially alter the stock's near-term trajectory.

Implication

Investors should continue to monitor Eliquis revenue and gross margin as the key checkpoints for the 2026 guidance, rather than incremental Sotyktu data. Sotyktu's durable efficacy may help it gain modest share in the crowded psoriatic arthritis market, but competitive intensity limits upside. The stock's near-term performance will likely be driven by Q1/Q2 2026 earnings, particularly whether Eliquis stays on track for +10–15% growth while consolidated gross margin holds at 69–70%. Failure on either metric would validate bear-case concerns, while confirmation could support a move toward the $65 base-case value. Overall, this news does not justify changing positioning; the WAIT rating and attractive entry near $55 remain appropriate.

Thesis delta

The investment thesis is unchanged: BMY remains a policy-fragile bridge-year story with observable checkpoints on Eliquis and Revlimid. The Sotyktu data provides incremental evidence of Growth Portfolio durability but does not shift the probabilities of the base, bear, or bull scenarios. The key risks—IRA price resets, Revlimid volume-cap removal, and gross margin defense—are unaffected by this clinical update.